Morgan Stanley Sees Attractive Entry Point for Abbott Laboratories
In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Overweight rating and $45.00 price target on Abbott Laboratories (NYSE: ABT).
In the report, Morgan Stanley noted, “The most challenging quarter of the year is behind the company and we see clarity to acceleration ahead. Consensus under-appreciates margin momentum into 2H14 and 15'. As EPS and revenue move higher into 2Q, shares will follow. Reiterate our OW thesis and $45 target.”
Abbott Laboratories closed on Wednesday at $38.38.
Latest Ratings for ABT
|Mar 2017||BMO Capital||Downgrades||Outperform||Market Perform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.